Xeris Pharmaceuticals ( (XERS) ) has released its Q1 earnings. Here is a breakdown of the information Xeris Pharmaceuticals presented to its investors.
Xeris Biopharma Holdings, Inc. is a rapidly expanding biopharmaceutical company focused on developing and commercializing innovative therapies, with a portfolio that includes treatments for conditions such as endogenous Cushing’s syndrome and severe hypoglycemia.
In its latest earnings report, Xeris Biopharma announced a significant 48% year-over-year increase in total revenue for the first quarter of 2025, reaching over $60 million. The company has also updated its full-year revenue guidance, reflecting strong performance and confidence in its strategic initiatives.
Key highlights from the report include a remarkable 141% growth in Recorlev® revenue, driven by a substantial increase in patient numbers. Gvoke® also saw a 26% rise in revenue, while Keveyis® experienced a slight decline. Additionally, the company achieved FDA approval for Gvoke VialDx™ and received a milestone payment from its partner, contributing to its other revenue streams. Despite a net loss of $9.2 million, Xeris reported a positive adjusted EBITDA of $4.4 million, marking a significant improvement from the previous year.
Looking ahead, Xeris Biopharma remains optimistic about its growth trajectory, with tightened revenue guidance for 2025 and plans to host an Investor and Analyst Day to discuss future growth drivers. The company continues to focus on executing its growth strategy and delivering value to patients and shareholders.